Brief: Regen Biopharma Inc research demonstrates ex-vivo immune suppression with novel nr2f6 activators
25/07/2017 13:03
July 25 (Reuters) - Regen Biopharma Inc RGBP.PK :
* Regen Biopharma Inc Research demonstrates ex-vivo immune
suppression with novel nr2f6 activators
Source text for Eikon: ID:nPn2StL6la
Further company coverage: RGBP.PK
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Regen BioPharma
See all newsBrief: Regen Biopharma Prepares Response For FDA Regarding Its Orphan Drug Application For HemaXellerate
Brief: Regen Biopharma Expands Vision For Phase 1 Clinical Trial Of Hemaxellerate
Brief: Regen Biopharma, Inc. Receives First Phase Of Confirmatory Study
Brief: Regen Biopharma Files Provisional Patent On Car-T Cell Capable Of Attracting And Educating Naïve T Cells
Brief: Regen Biopharma addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics